Miscellaneous - Oxford Journals - Oxford University Press

2 downloads 0 Views 29KB Size Report
Oncology Center, Rabat, MOROCCO, 3Laboratory of Genetics and Biometry,. Faculty of Sciences ... European Society for Medical Oncology 2013. Published by ...
Annals of Oncology 24 (Supplement 3): iii48–iii50, 2013 doi:10.1093/annonc/mdt089.4

Miscellaneous 117P

EPIDEMIOLOGICAL CHARACTERISTICS OF BREAST CANCER IN MOROCCO

A. Ayoujil1, F. Habib2, H. Hami3, A. Soulaymani3, A. Mokhtari3, A. Quyou3 1 Faculty of Sciences, Ibn Tofail University, Kenitra, MOROCCO, 2Al Azhar, Oncology Center, Rabat, MOROCCO, 3Laboratory of Genetics and Biometry, Faculty of Sciences, Ibn Tofail University, Kenitra, MOROCCO

abstracts

Introduction: Breast cancer is the most common cause of cancer death in women worldwide. The aim of this study is to describe the epidemiological characteristics of breast cancer in Morocco.

Methods: A retrospective analysis of breast cancer cases diagnosed and treated at Al Azhar Oncology Center in Rabat between 1994 and 2004, was performed. Results: During 1994-2004, 1710 cases were diagnosed with breast cancer at Al Azhar Oncology Center, 97.5% in women and 2.5% in men, giving a female-male ratio of around 39 and accounting for 24% of all cancer cases reported during this period. The average age at diagnosis was 47 years. The risk of developing breast cancer is strongly related to age with 8.2% of new breast cancer cases diagnosed in persons younger than 35 years, 85.2% in those aged 35-64 years and 6.7% in those aged 65 years and over. Among all detected cases, 2% are metastatic at diagnosis and 208 (12.2%) breast cancer cases, including 200 women died during the study period. Conclusions: Breast cancer was the leading cause of death from cancer in women. Early detection in order to improve breast cancer outcome and survival remains the cornerstone of breast cancer control. Disclosure: All authors have declared no conflicts of interest.

© European Society for Medical Oncology 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].